Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy - - BioPharm International

ADVERTISEMENT

Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy


blog comments powered by Disqus


Angie Drakulich, Editorial Director of BioPharm International, talks with Mike Clayman, CEO of Flexion Therapeutics. Based in Woburn, MA, the company works to develop therapeutics for musculoskeletal disorders. In this podcast, Clayman discusses why the company chose to focus on a full range of treatments for one particular disease, osteoarthritis, and how the approach has helped the company fill its biopharmaceutical pipeline and market space. Posted Apr. 2012.

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here